Steady State Calculator

Enter a drug's half-life and dosing interval to determine the time to reach steady state and the accumulation ratio (Rac). The accumulation ratio indicates how much drug accumulates with repeated dosing compared to a single dose. A high t½/τ ratio (>1) indicates significant accumulation requiring clinical monitoring.

Half-Life (hours)

Dosing Interval (hours)

Common: 6h (QID), 8h (TID), 12h (BID), 24h (QD)

Time to Steady State

(97% of SS, 5 × t½)

Accumulation Ratio (Rac)

Trough at SS / Single-dose trough

t½ / τ Ratio

>1 = significant accumulation

Clinical Interpretation

Understanding Steady-State Concentration

Steady-state (Css) is the plasma drug concentration achieved when the rate of drug input equals the rate of elimination during repeated dosing. Under first-order kinetics, steady state is reached after approximately five elimination half-lives regardless of dose size or dosing frequency. At steady state, the average, peak (Cmax,ss), and trough (Cmin,ss) plasma concentrations follow predictable patterns that determine whether a drug remains within its therapeutic window throughout each dosing interval.

The accumulation ratio (Rac) quantifies how much drug builds up relative to a single dose. When the dosing interval is shorter than the half-life (t½/τ > 1), significant accumulation occurs and Rac exceeds 1. For example, a drug with a 24-hour half-life dosed every 12 hours has an Rac of approximately 2 — meaning the trough at steady state is twice what it was after the first dose. Recognizing this accumulation is clinically important for drugs with narrow therapeutic indices, such as digoxin, lithium, or aminoglycoside antibiotics, where supratherapeutic concentrations can cause toxicity.

Loading doses are used to rapidly achieve steady-state concentrations when waiting five half-lives is clinically impractical. A loading dose is calculated as the target Css multiplied by the volume of distribution, bypassing the gradual accumulation phase. This strategy is standard for drugs like amiodarone (t½ ~50 days), phenytoin, and vancomycin, where achieving therapeutic levels quickly can be lifesaving. Therapeutic drug monitoring (TDM) during the attainment phase helps confirm that predicted and actual concentrations align.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

How to Use

1
Enter dose, dosing interval, and half-life
Input the dose (in mg or µg), dosing interval (hours), and elimination half-life (hours) for the drug. For drugs with linear pharmacokinetics, the steady-state concentration is determined solely by these three parameters plus clearance or bioavailability.
2
Calculate time to steady state and predicted concentrations
The tool calculates the number of half-lives required to reach 90% of steady state (3.32 half-lives) and 97% (5 half-lives), and predicts steady-state trough (Css,min) and peak (Css,max) concentrations using first-order accumulation equations, assuming constant dosing and first-order elimination.
3
Apply clinical context
Interpret results against the drug's therapeutic range where published. The tool displays whether predicted steady-state concentrations fall within, above, or below the therapeutic window, and calculates the accumulation ratio (Css,max / single-dose Cmax) to quantify drug accumulation over repeated dosing.

About

Steady-state pharmacokinetics governs the therapeutic behavior of drugs administered by repeated dosing regimens, which is the standard approach for the management of chronic conditions requiring sustained drug exposure. The principle that drug accumulation ceases when input rate equals elimination rate — described mathematically by the relationship Css,avg = F × Dose / (CL × τ) — provides a rational framework for dose selection, dosing interval determination, and therapeutic drug monitoring.

Loading dose strategies exploit the relationship between desired concentration and volume of distribution to achieve rapid attainment of therapeutic levels without waiting for spontaneous accumulation through repeated dosing. The loading dose equation LD = Vd × Css,target / F is applied for digoxin, loading antiepileptics, lidocaine infusions, and heparin boluses in clinical practice, allowing immediate therapeutic action while subsequent maintenance doses sustain concentrations within the target range. In ICU settings, pharmacist-led PK-guided dosing for antibiotics such as vancomycin and piperacillin-tazobactam uses real-time plasma level monitoring and Bayesian-adjusted PK parameters to optimize individual steady-state exposures for target attainment.

This steady-state calculator implements first-order accumulation equations validated against standard pharmacokinetic modeling, providing clinically oriented outputs including time to steady state, predicted peak and trough concentrations, and accumulation ratio. Results are intended to support pharmacokinetic education and provide a computational framework for understanding the implications of drug half-life and dosing interval on drug accumulation. All predictions assume linear pharmacokinetics and should be supplemented by patient-specific therapeutic drug monitoring and clinical assessment for drugs with documented non-linear kinetics or narrow therapeutic indices.

FAQ

What is pharmacokinetic steady state and why is it clinically important?

Pharmacokinetic steady state is the condition achieved with multiple-dose drug administration when the rate of drug input equals the rate of elimination, resulting in stable average plasma concentrations over each dosing interval. Clinically, steady state marks the point at which drug effects are fully established at the prescribed dose — patients may experience incomplete therapeutic effects before steady state is reached with long-half-life drugs, and dose adjustments made before steady state can lead to under- or overdosing. At steady state, average plasma concentration (Css,avg) equals bioavailable dose divided by (clearance × dosing interval), a relationship that guides rational dose adjustment when clinical monitoring indicates concentrations outside the therapeutic range.

How many doses are needed to reach steady state?

For drugs with linear (first-order) pharmacokinetics, approximately 4 to 5 half-lives of multiple dosing are required to reach 94% and 97% of steady-state concentration, respectively, regardless of dose or dosing interval. This universal principle means that amiodarone (t½ 40–55 days) requires months to reach steady state at maintenance doses, while ciprofloxacin (t½ 4 hours) reaches steady state within one day. Loading doses are used for drugs requiring rapid therapeutic effect where waiting 4 to 5 half-lives for spontaneous accumulation would delay benefit; loading doses for digoxin, lidocaine, and heparin are calculated to achieve therapeutic concentrations immediately.

What is the accumulation ratio and how is it calculated?

The accumulation ratio (R) compares the peak plasma concentration at steady state to the peak after a single dose, quantifying total drug accumulation over the multiple-dose regimen. It is calculated as R = 1 / (1 − e^(−k_el × τ)), where k_el is the elimination rate constant (0.693 / t½) and τ is the dosing interval. Drugs with a dosing interval much shorter than their half-life (τ << t½) accumulate substantially (high R), while drugs dosed at intervals equal to or longer than their half-life (τ ≥ t½) show minimal accumulation. This calculation is important for assessing toxicity risk at steady state relative to initial dosing in drugs with extended half-lives.

How does non-linear pharmacokinetics affect steady state predictions?

Steady-state concentration predictions based on linear pharmacokinetics (where clearance is constant regardless of concentration) do not apply to drugs exhibiting Michaelis-Menten or saturable kinetics. For phenytoin, increasing the dose from 300 to 400 mg/day can increase steady-state concentrations from therapeutic to toxic levels because elimination becomes increasingly saturated as concentrations approach the Km. Ethanol, aspirin, and some antiretrovirals also exhibit concentration-dependent clearance. For these drugs, empirical therapeutic drug monitoring using measured plasma levels rather than calculated predictions is essential for dosing in the clinical steady-state range.

What factors can alter predicted steady-state concentrations in individual patients?

Actual steady-state concentrations may deviate from predictions due to patient-specific pharmacokinetic variability including altered bioavailability (modified by food, antacids, or GI disease), changes in volume of distribution (altered by age, body composition, fluid status, or plasma protein concentration), and changes in clearance (affected by renal or hepatic function, drug interactions, and genetic polymorphisms). Adherence patterns also affect steady state; missed doses create fluctuations that transiently reduce concentrations below steady-state predictions. Therapeutic drug monitoring with measured trough or peak levels combined with Bayesian estimation algorithms provides the most accurate individualized steady-state assessment for narrow therapeutic index drugs.